Moderna mRNA Vaccine Nearly Halves Melanoma Recurrence
A Phase 2b/3 trial of Moderna's personalised mRNA melanoma vaccine combined with Keytruda has shown a 44% reduction in recurrence or death at the three-year mark versus Keytruda alone, extending the lead from earlier results.
- 44% relative risk reduction in recurrence-free survival at 36 months
- Vaccine codes for up to 34 neoantigens personalised to each patient's tumour
- Moderna expects Phase 3 data in 2028; regulatory path under discussion with FDA